NO940663L - Lyofilisert polyalkylenoksid modifisert protein og polypeptid komplekser med cyclodextrin - Google Patents

Lyofilisert polyalkylenoksid modifisert protein og polypeptid komplekser med cyclodextrin

Info

Publication number
NO940663L
NO940663L NO940663A NO940663A NO940663L NO 940663 L NO940663 L NO 940663L NO 940663 A NO940663 A NO 940663A NO 940663 A NO940663 A NO 940663A NO 940663 L NO940663 L NO 940663L
Authority
NO
Norway
Prior art keywords
cyclodextrin
polyalkylene oxide
lyophilized
modified protein
oxide modified
Prior art date
Application number
NO940663A
Other languages
English (en)
Norwegian (no)
Other versions
NO940663D0 (no
Inventor
Christopher P Phillips
Robert A Snow
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Publication of NO940663D0 publication Critical patent/NO940663D0/no
Publication of NO940663L publication Critical patent/NO940663L/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083—Neurotensin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO940663A 1993-02-25 1994-02-25 Lyofilisert polyalkylenoksid modifisert protein og polypeptid komplekser med cyclodextrin NO940663L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/023,182 US5298410A (en) 1993-02-25 1993-02-25 Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life

Publications (2)

Publication Number Publication Date
NO940663D0 NO940663D0 (no) 1994-02-25
NO940663L true NO940663L (no) 1994-08-26

Family

ID=21813561

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940663A NO940663L (no) 1993-02-25 1994-02-25 Lyofilisert polyalkylenoksid modifisert protein og polypeptid komplekser med cyclodextrin

Country Status (18)

Country Link
US (4) US5298410A (ru)
EP (1) EP0614666A1 (ru)
JP (1) JPH06256222A (ru)
KR (1) KR940019312A (ru)
AU (1) AU660843B2 (ru)
CA (1) CA2106519A1 (ru)
CZ (1) CZ38194A3 (ru)
FI (1) FI940909A (ru)
HU (1) HUT71586A (ru)
IL (1) IL108777A (ru)
MX (1) MX9305528A (ru)
MY (1) MY131553A (ru)
NO (1) NO940663L (ru)
NZ (1) NZ248590A (ru)
PH (1) PH30462A (ru)
RU (1) RU94006023A (ru)
SK (1) SK23294A3 (ru)
TW (1) TW260611B (ru)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
CA2114163C (en) * 1993-01-29 2002-04-30 Nobuo Nishiki Method for stabilizing antigenicity of myeloperoxidase
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
FR2703927B1 (fr) * 1993-04-13 1995-07-13 Coletica Utilisation d'une réaction de transacylation entre un polysaccharide estérifié et une polyamine pour former en milieu aqueux une membrane au moins en surface de particules gélifiées.
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
JPH0776700A (ja) * 1993-07-14 1995-03-20 Senju Pharmaceut Co Ltd コンタクトレンズ用剤の安定化方法
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
MX9704137A (es) * 1994-12-07 1997-09-30 Novo Nordisk As Polipeptidos de alergenicidad reducida.
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
US5861148A (en) * 1995-01-23 1999-01-19 Smith; Stewart Gregory Ophthalmic compositions and process of using
ATE257844T1 (de) * 1995-03-10 2004-01-15 Nakamura Toshikazu Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol
US5756593A (en) * 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US5868868A (en) * 1995-06-19 1999-02-09 Alcon Laboratories, Inc. Peg-modified proteases and methods of use in contact lens cleaning
JPH11502255A (ja) * 1995-12-29 1999-02-23 ザ、プロクター、エンド、ギャンブル、カンパニー 固定化酵素を含有する洗剤組成物
DE69733664T3 (de) * 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
AU4981897A (en) * 1996-10-15 1998-05-11 Navix, Inc. Stabilized conjugates of uncomplexed subunits of multimeric proteins
US6321909B1 (en) * 1997-02-13 2001-11-27 Sky High, Llc System for storing polyethylene glycol solutions
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US7642323B2 (en) * 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
GB9815785D0 (en) * 1998-07-20 1998-09-16 Cerebrus Ltd Chemical compounds
ATE498409T1 (de) 1998-08-06 2011-03-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US6994686B2 (en) * 1998-08-26 2006-02-07 Neomend, Inc. Systems for applying cross-linked mechanical barriers
DK1121156T3 (da) 1998-10-16 2006-06-06 Biogen Idec Inc Polymerkonjugater af interferon-beta-1a samt deres anvendelse
BR9915548A (pt) * 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
US7279001B2 (en) * 1998-11-06 2007-10-09 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
EP1282411A4 (en) * 2000-04-26 2008-05-21 Charlotte Mecklenburg Hospital ANTICANCER TREATMENT METHOD
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
SG98393A1 (en) * 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US8394813B2 (en) * 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
US7195923B2 (en) * 2001-01-31 2007-03-27 Scripps Laboratories, Inc. Ratiometric determination of glycated protein
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
WO2002094324A1 (en) * 2001-05-18 2002-11-28 Institute Of Materials Research & Engineering Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
ATE376020T1 (de) 2001-08-22 2007-11-15 Bioartificial Gel Technologies Inc Verfahren zu herstellung von aktivierten polyethylenglykolen
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
WO2003072046A2 (en) * 2002-02-22 2003-09-04 New River Pharmaceuticals Inc. Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US20050132430A1 (en) * 2001-12-21 2005-06-16 Mogens Baltsen Igamete recruitment and developmental competence in mammals by inhibiting the de-nova sterol biosynthesis and/or promoting sterol efflux
CN1620499A (zh) * 2001-12-21 2005-05-25 哥本哈根大学医院 哺乳动物的配子募集和发育能力－通过抑制固醇从头生物合成和/或促进固醇外流
EP3669887A1 (en) 2002-01-18 2020-06-24 Biogen MA Inc. Polyalkylene polymer compounds and uses thereof
WO2003072637A1 (en) * 2002-02-22 2003-09-04 Insert Therapeutics, Inc. Carbohydrate-modified polymers, compositions and uses related thereto
CN1649614A (zh) * 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7659253B2 (en) * 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
JP4723244B2 (ja) 2002-07-19 2011-07-13 オメロス コーポレイション 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料
CN102516417B (zh) 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
AU2004251647B2 (en) * 2003-05-29 2010-01-14 Takeda Pharmaceutical Company Limited Abuse resistant amphetamine compounds
PL1656410T3 (pl) 2003-07-22 2010-08-31 Nektar Therapeutics Sposób wytwarzania sfunkcjonalizowanych polimerów z polimerycznych alkoholi
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
ES2733764T3 (es) * 2003-12-16 2019-12-02 Nektar Therapeutics Método para la preparación de oligo etilenglicol monodisperso
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
CN100355786C (zh) * 2004-04-28 2007-12-19 江苏豪森药业股份有限公司 聚乙二醇修饰的胸腺肽1衍生物
AU2005269753B2 (en) 2004-07-19 2011-08-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US8080423B2 (en) * 2004-08-05 2011-12-20 Asahi Kasei Pharma Corporation Reagent containing protease reaction promoter and/or colorant stabilizer
TW200640493A (en) * 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery
SG10201706384VA (en) * 2005-04-11 2017-09-28 Crealta Pharmaceuticals Llc A variant form of urate oxidase and use thereof
WO2006110819A2 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP1896610A2 (en) * 2005-05-03 2008-03-12 Handylab, Inc. Lyophilized pellets
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US8568705B2 (en) 2005-07-18 2013-10-29 Nektar Therapeutics Method for preparing branched functionalized polymers using branched polyol cores
KR100664969B1 (ko) * 2005-08-26 2007-01-04 아이디비켐(주) 고순도의 메톡시폴리에틸렌글리콜 및 그들의 유도체의제조방법
CN100360666C (zh) * 2005-11-29 2008-01-09 沈阳农业大学 一种修饰玉米sod的方法
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
US20070173634A1 (en) * 2006-01-24 2007-07-26 Olsson Nils U Methods for one-step purification of organic polymers using tangential flow filtration
ES2532804T3 (es) * 2006-04-12 2015-03-31 Crealta Pharmaceuticals Llc Purificación de proteínas con tensioactivo catiónico
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2113009B1 (en) * 2007-02-22 2018-11-21 Biovectra Inc. Process for purification of water soluble polymers
JP4697809B2 (ja) * 2007-02-22 2011-06-08 旭化成ファーマ株式会社 ロイコ色素の安定化方法
RU2007131782A (ru) * 2007-08-22 2009-02-27 Общество с ограниченной ответственностью "Концерн O3" (RU) Гипогликемическое средство и способ его получения
RU2007137048A (ru) * 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) Лекарственное средство для лечения и предупреждения осложнений при сахарном диабете
RU2007137044A (ru) * 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) Лекарственное средство, обладающее гемопоэзстимулирующим и гепатопротекторным действием
PT2203181T (pt) * 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
JP5569787B2 (ja) * 2009-03-31 2014-08-13 日油株式会社 高分子量ポリエチレングリコール化合物の精製方法
JP5713274B2 (ja) 2009-03-31 2015-05-07 日油株式会社 高分子量ポリオキシアルキレン誘導体の精製方法
BRPI1010069A2 (pt) 2009-06-25 2016-03-15 Savient Pharmaceuticals Inc "método para prevenir reações à infusão durante terapia por uricase peguilada em pacientes; e método para diagnosticar se um paciente tratado com uricase peguilada desenvolverá reações à infusão ou desenvolverá liberação de uricase peguilada mediada por anticorpo sem a medição de títulos de anticorpos anti-peg e anti-uricase peguilada"
CN104208716A (zh) * 2009-11-23 2014-12-17 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
WO2011119995A2 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
GB201008902D0 (en) 2010-05-27 2010-07-14 Imp Innovations Ltd Membrane enhanced polymer sythesis
US8163869B1 (en) 2010-12-27 2012-04-24 Nof Corporation Purification method of carboxyl group-containing polyoxyethylene derivative
RU2452509C1 (ru) * 2011-01-31 2012-06-10 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" ООО "Саентифик Фьючер Менеджмент" Средство для стимуляции роста организма
US9090769B2 (en) 2011-04-05 2015-07-28 Ticona Llc Molded articles having a swirl-like or marble-like appearance and compositions for producing same
WO2012145632A1 (en) * 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN114917185B (zh) 2016-10-21 2023-11-14 美国安进公司 药物配制品及其制备方法
CN111936549B (zh) * 2018-03-29 2023-03-10 日油株式会社 包含三苯甲基的单分散聚乙二醇的纯化方法
EP3810089B1 (en) * 2018-06-07 2023-08-02 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
CN109206598A (zh) * 2018-09-10 2019-01-15 武汉轻工大学 聚乙二醇-聚丙交酯嵌段共聚物的制备方法以及药物载体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPH084504B2 (ja) * 1985-04-26 1996-01-24 味の素株式会社 安定化ス−パ−オキサイドジスムタ−ゼ
US4970216A (en) * 1986-03-17 1990-11-13 Richardson Vicks, Inc. Skin treatment composition and method
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5183809A (en) * 1990-02-15 1993-02-02 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
US5182270A (en) * 1989-08-03 1993-01-26 Iolab Corporation Stabilizing preparation for thymoxamine
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5145644A (en) * 1990-12-20 1992-09-08 Allergan, Inc. Hydrogen peroxide destroying compositions and methods of making and using same
JPH04248984A (ja) * 1991-02-05 1992-09-04 Kuraray Co Ltd スーパーオキシドジスムターゼ誘導体およびその製造方法
CA2101361A1 (en) * 1992-08-27 1994-02-28 Robert A. Snow Low diol polyalkylene oxide biologically active proteinaceous substances
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life

Also Published As

Publication number Publication date
NZ248590A (en) 1995-07-26
EP0614666A1 (en) 1994-09-14
FI940909A (fi) 1994-08-26
PH30462A (en) 1997-05-28
HU9400561D0 (en) 1994-05-30
RU94006023A (ru) 1996-04-20
SK23294A3 (en) 1995-02-08
JPH06256222A (ja) 1994-09-13
US5298410A (en) 1994-03-29
NO940663D0 (no) 1994-02-25
FI940909A0 (fi) 1994-02-25
MX9305528A (es) 1994-08-31
CA2106519A1 (en) 1994-08-26
MY131553A (en) 2007-08-30
US5334382A (en) 1994-08-02
TW260611B (ru) 1995-10-21
IL108777A0 (en) 1994-06-24
KR940019312A (ko) 1994-09-14
HUT71586A (en) 1995-12-28
AU660843B2 (en) 1995-07-06
CZ38194A3 (en) 1994-10-19
US5529915A (en) 1996-06-25
IL108777A (en) 1998-02-08
AU4616293A (en) 1994-09-01
US5389381A (en) 1995-02-14

Similar Documents

Publication Publication Date Title
NO940663L (no) Lyofilisert polyalkylenoksid modifisert protein og polypeptid komplekser med cyclodextrin
DE69028739T2 (de) Modifizierte PF4-Zusammensetzung und Methoden zu deren Verwendung
ATE107514T1 (de) Stabilisierte protein- oder peptidkonjugate.
US9187529B2 (en) Cationic peptides and use of such peptides for inhibiting exotoxin production
EP1234586A3 (en) Hepatoselective pharmaceutical actives
TW427905B (en) Aqueous pharmaceutical composition of nerve growth factor
TR199701078T1 (xx) Monomerik ins�lin analogu form�lasyonlar.
JPH0674208B2 (ja) ＧＨＬ−Ｃｕの創傷治癒および抗炎症剤としての使用
EP0861667A3 (en) Particulate agents
DE69531332D1 (de) Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert
KR950703999A (ko) 변성된 인슐린-유사 성장인자(modified insulin-like growth factors)
DE59904569D1 (de) Therapeutikum zur unterdrückung von schnarchgeräuschen
DE60012557D1 (de) Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
AU2006203246A1 (en) Compositions and methods for regulating phagocytosis and ICAM-1 expression
DE69009748D1 (de) Fgf enthaltende stabilisierte zubereitungen.
WO2016183277A1 (en) Materials for tissue regeneration
Kurki et al. Characterization of human smooth muscle autoantibodies reacting with cytoplasmic intermediate filaments
JPH08510260A (ja) Ｌｈｒｈ拮抗剤
DE69129463D1 (de) Verwendung von substanzen in partikelform
EP1212094A2 (en) Delivery of antimicrobial toxins
FR2665363B1 (fr) Composition pharmaceutique comprenant une ou des bleomycines, et une ou des proteines inactivant les bleomycines.
WO1998021231A3 (en) Streptococcus uberis lactoferrin-binding protein
Reddy Binding between Pseudomonas aeruginosa adhesins and human salivary, tracheobronchial and nasopharyngeal mucins